Compare Cassava Sciences Inc (FLNA) vs Plug Power Inc (PLUG) Price & Performance

Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.

The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.

Plug Power trades at $2.27, up 4.61% today but remains in a bearish technical trend with negative profitability metrics. The company reported a net loss of $1.63 billion on $710 million revenue in 2025, though recent quarterly earnings showed mixed results with a Q1 2026 miss. News highlights include a 50MW electrolyzer order in Australia and asset sales aimed at boosting liquidity, while analyst consensus is divided with a $2.92 price target.

The outlook hinges on Plug Power's path to projected 2028 profitability amid persistent cash burn and high short interest. Investment opportunity exists in hydrogen ecosystem growth, but risks include sustained losses, competitive pressure, and execution challenges in scaling operations globally.